PD-1/PD-L1 therapies allows T cells to be effectively activated, thus restoring the body’s immune function to achieve anti-tumor effects, which is also believed to be a radiation enhancement factor (Wang et al., 2019; Vanneste et al., 2020). Here, CD274 is linked to neoplasm.